Chancellor John R, Kilgore David A, Sallam Ahmed B, Allen Richard C, Uwaydat Sami H
Jones Eye Institute, Department of Ophthalmology, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.
University of Arkansas for Medical Sciences, College of Medicine, Little Rock, Arkansas, USA.
Case Rep Ophthalmol. 2019 Oct 9;10(3):334-338. doi: 10.1159/000503414. eCollection 2019 Sep-Dec.
The mitogen-activated kinase pathway plays an important role in cell survival, and its dysregulation is associated with cancers such as melanoma. Drugs designed to target this pathway have been associated with serous retinal detachments in a new entity termed MEK inhibitor-associated retinopathy (MEKAR). MEKAR has classically been described as self-limiting, with serous fluid often resolving without discontinuation of the drug. We present a case in which a patient undergoing treatment for metastatic melanoma with lacnotuzumab, a macrophage colony-stimulating factor inhibitor that blocks an upstream component of the mitogen-activated protein kinase pathway, developed serous retinopathy that did not resolve despite drug discontinuation.
丝裂原活化激酶通路在细胞存活中起重要作用，其失调与黑色素瘤等癌症相关。针对该通路设计的药物与一种称为MEK抑制剂相关视网膜病变（MEKAR）的新病症中的浆液性视网膜脱离有关。MEKAR传统上被描述为自限性，浆液性积液通常在不停用药物的情况下消退。我们报告一例病例，一名接受拉克奴单抗治疗转移性黑色素瘤的患者，拉克奴单抗是一种巨噬细胞集落刺激因子抑制剂，可阻断丝裂原活化蛋白激酶通路的上游成分，该患者发生了浆液性视网膜病变，尽管停用了药物但仍未消退。
